Jubilant Life Sciences has suffered drop during the fourth quarter ended March 2015 due to lower sales and its consolidated net profit declined sharply by 56.8 per cent to Rs.42.73 crore from Rs.98.81 crore in the corresponding period of last year. Its consolidated net sales also declined by 1.9 per cent to Rs.1,523 crore from Rs.1,552 crore. EBIDTA improved marginally to Rs.253.27 crore from Rs.250.86 crore. EPS declined to Rs.2.68 from Rs.6.20 in the last period. The company management recommended equity dividend of 300 % for the year 2014-15.
Its pharmaceutical revenue improved to Rs.763 crore from Rs.705 crore and that of life science ingredients (LSI) segment declined to Rs.774 crore from Rs.859 crore. Its international revenues contributed 73 per cent to its revenue and reached at Rs.1,115 core during the fourth quarter ended March 2015. Its revenue from North America reached at Rs.621 crore and of Europe stood at Rs.284 crore. Its revenue from China stood at Rs.209 crore. For the full year ended March 2015, Jubilant Life has incurred a heavy consolidated net loss of Rs.58 crore as against a net profit of Rs.109 crore in the previous year. Its consolidated net sales increased marginally to Rs.5,776 crore from Rs.5,724 crore. EBIDTA declined by 28.7 per cent to Rs.732 crore from Rs.1,027 crore.
Jubilant's pharmaceutical sales decreased by 1.7 per cent to Rs.2,682 crore from Rs.2,728 crore in the previous year. However, its LSI revenues improved to Rs.3,150 crore from Rs.2,079 crore. Pharmaceutical sales contributed 46 per cent to its total sales and LSI contributed remaining 54 per cent. Its international sales contributed 71 per cent to the overall revenues at Rs.4,157 crore. The company's sales in North America still at Rs.2,191 crore, contributed 38 per cent to the revenue mix. Similarly, its revenues from Europe and Japan stood at Rs.1,175 crore and contributed 20 per cent to total sales. Domestic revenue improved by 13 per cent to Rs.1,669 crore and domestic share in sales worked out to 29 per cent.
The company expects revenue growth is to be driven by pharmaceuticals segment primarily led by improved performance in radiopharmaceuticals and growth in its generic business through new product and new market launches.
Subscribe to PharmaTutor News Alerts by Email >>
